AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15064389 — intervention group
Group type: EXPERIMENTAL
Intervention: 14‐Gy centered endovascular irradiation (irradiation group, n = 15)
Number of subjects: 30
Study 15064389 — intervention group
Group type: COMPARATOR
Intervention: No irradiation (control group, n = 15)
Number of subjects: 30
Study 15064389 — intervention group
Group type: EXPERIMENTAL
Intervention: 14‐Gy centered endovascular irradiation (irradiation group)
Number of subjects: 30
Study 15064389 — intervention group
Group type: COMPARATOR
Intervention: No irradiation (control group)
Number of subjects: 30
Study 11566069 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg) administered intravenously during dehydration
Number of subjects: 7
Study 11566069 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no furosemide, hydration maintained)
Number of subjects: 7
Study 11566069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration (induced by furosemide)
Number of subjects: 7
Study 11566069 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with glucagon
Number of subjects: 7
Study 11566069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration effects on potassium and sodium excretion
Number of subjects: 7
Study 11566069 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in reactivity of urea synthesis to glucagon
Number of subjects: 7
Study 9714487 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with CPB
Number of subjects: 57
Study 9714487 — intervention group
Group type: COMPARATOR
Intervention: MIDCAB without CPB
Number of subjects: 57
Study 9248869 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride 20 mg daily for 6 weeks
Number of subjects: 79
Study 1937608 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter with stillete
Number of subjects: 100
Study 1937608 — intervention group
Group type: COMPARATOR
Intervention: Catheter without stillete
Number of subjects: 100
Study 7095604 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) and dihydroergotamine (DHE) combined treatment
Number of subjects: 150
Study 7095604 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) alone
Number of subjects: 150
Study 7095604 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine (DHE) alone
Number of subjects: 150
Study 30397078 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM implementation
Number of subjects: 230099
Study 30235716 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine (0.25 mg/kg)
Number of subjects: 0
Study 30235716 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 0
Study 26485439 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment at 14 cm H2 O
Number of subjects: 54
Study 26485439 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment at 0 cm H2 O
Number of subjects: 54
Study 24711067 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroAiD
Number of subjects: 150
Study 24711067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 22892913 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 16
Study 22892913 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 16
Study 20150747 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist care (SP)
Number of subjects: 308
Study 20150747 — intervention group
Group type: COMPARATOR
Intervention: General practitioner care (GP)
Number of subjects: 308
Study 18611277 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised walking programme (3 sessions of 50 minutes per week for 6 months)
Number of subjects: 106
Study 18611277 — intervention group
Group type: COMPARATOR
Intervention: Best primary care (control group)
Number of subjects: 106
Study 16010540 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 and 0.1 mg of pergolide (direct DA agonist)
Number of subjects: 32
Study 16010540 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 and 200 mg of amantadine (indirect DA agonist)
Number of subjects: 32
Study 16010540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11899956 — intervention group
Group type: EXPERIMENTAL
Intervention: Silzone valves
Number of subjects: 807
Study 11899956 — intervention group
Group type: COMPARATOR
Intervention: Conventional valves
Number of subjects: 807
Study 10087750 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 72
Study 10087750 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus azathioprine
Number of subjects: 72
Study 10087750 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone‐cyclophosphamide pulse (BCP) therapy
Number of subjects: 72
Study 10087750 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine-corticosteroid treatment
Number of subjects: 72
Study 7836734 — intervention group
Group type: COMPARATOR
Intervention: Captopril (150 mg/day for 3 days)
Number of subjects: 6
Study 7836734 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat (0.2 mg/kg per h) during exercise
Number of subjects: 6
Study 7836734 — intervention group
Group type: COMPARATOR
Intervention: Saline during exercise
Number of subjects: 6
Study 3350283 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon distention of the stomach with 100, 200, or 300 ml of water
Number of subjects: 16
Study 3350283 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of lipid into the duodenum at 1.5 ml/min for 30 min
Number of subjects: 16
Study 3350283 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 16
Study 3350283 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of cholecystokinin-octapeptide intravenously at 20 ng/kg.h
Number of subjects: 16
Study 29282713 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 308
Study 29282713 — intervention group
Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 308
Study 27957559 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration and fluoride varnish (RI+FV)
Number of subjects: 81
Study 27957559 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish only (FV)
Number of subjects: 81
Study 24675911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise circuit session at moderate intensity (3 laps of knee extension, bench press, knee flexion, rowing, squats, shoulder press, and 5 min of aerobic exercise at 75‐85% of age‐predicted maximum heart rate; resistance exercise at 50% of estimated 1 repetition maximum for 15 repetitions)
Number of subjects: 20
Study 24675911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise circuit session at moderate intensity
Number of subjects: 20
Study 24675911 — intervention group
Group type: COMPARATOR
Intervention: Control session with no exercise
Number of subjects: 20
Study 22215918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Sleep Retraining (ISR)
Number of subjects: 79
Study 22215918 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus Control Therapy (SCT)
Number of subjects: 79
Study 22215918 — intervention group
Group type: EXPERIMENTAL
Intervention: ISR plus SCT
Number of subjects: 79
Study 22215918 — intervention group
Group type: COMPARATOR
Intervention: Control (Sleep Hygiene)
Number of subjects: 79
Study 20831416 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignettes describing disclosure risk in informed consent statements
Number of subjects: 0
Study 20831416 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity of the survey topic
Number of subjects: 0
Study 20831416 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit mention of possible harms from disclosure
Number of subjects: 0
Study 20831416 — intervention group
Group type: EXPERIMENTAL
Intervention: Different wording of confidentiality assurance
Number of subjects: 0
Study 20831416 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental manipulations of risk and benefits perceptions
Number of subjects: 0
Study 20831416 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey topic
Number of subjects: 0
Study 18213383 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg daily for 12 months
Number of subjects: 51
Study 18213383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 16733278 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 20
Study 16733278 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal serum concentration of vitamin D, calcium, and phosphorus
Number of subjects: 20
Study 16733278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone turnover markers
Number of subjects: 20
Study 12888151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 103
Study 10232298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 108
Study 10232298 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 108
Study 10232298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 8905428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 100 mg by intravenous infusion 60 min before extubation
Number of subjects: 77
Study 8905428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline 3 cc)
Number of subjects: 77
Study 8905428 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 8905428 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence
Number of subjects: 77
Study 8905428 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 77
Study 8905428 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 77
Study 8905428 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk
Number of subjects: 77
Study 1475621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily for 7 days
Number of subjects: 15
Study 1475621 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg for 7 days
Number of subjects: 15
Study 1475621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6399247 — intervention group
Group type: EXPERIMENTAL
Intervention: High feedback real-time ultrasound
Number of subjects: 129
Study 6399247 — intervention group
Group type: COMPARATOR
Intervention: Low feedback real-time ultrasound
Number of subjects: 129
Study 6399247 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal movement at 16 weeks
Number of subjects: 129
Study 6399247 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery ratings of attachment to the neonate
Number of subjects: 129
Study 6399247 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactions to the neonate at delivery and postpartum mood ratings
Number of subjects: 129
Study 30747613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose on day 1, then 90 mg twice daily on days 2-30, plus open-label aspirin 300-325 mg on day 1, then 75-100 mg once daily on days 2-30.
Number of subjects: 13000
Study 30747613 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 300-325 mg on day 1, then 75-100 mg once daily on days 2-30 (control group).
Number of subjects: 13000
Study 29457538 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 60
Study 29457538 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 60
Study 26485203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for osteoarthritis pain
Number of subjects: 367
Study 26485203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for osteoarthritis pain and insomnia
Number of subjects: 367
Study 26485203 — intervention group
Group type: COMPARATOR
Intervention: Education-only control (EOC)
Number of subjects: 367
Study 25319187 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA diet (sunflower oil rich in polyunsaturated fatty acids)
Number of subjects: 39
Study 25319187 — intervention group
Group type: COMPARATOR
Intervention: SFA diet (palm oil rich in saturated fatty acids)
Number of subjects: 39
Study 25319187 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole group (independently of fat type)
Number of subjects: 39
Study 22669351 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 24
Study 22669351 — intervention group
Group type: COMPARATOR
Intervention: Travoprost
Number of subjects: 24
Study 22669351 — intervention group
Group type: COMPARATOR
Intervention: Tafluprost
Number of subjects: 24
Study 22669351 — intervention group
Group type: COMPARATOR
Intervention: Bimatoprost
Number of subjects: 24
Study 20403637 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 136
Study 20403637 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster Care Group (FCG)
Number of subjects: 136
Study 17542047 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (mean daily doses 357-496 mg/day)
Number of subjects: 4956
Study 17542047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4956
Study 17542047 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (10.4 mg/day)
Number of subjects: 4956
Study 17542047 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (5.5 mg/day)
Number of subjects: 4956
Study 17542047 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (552 mg/day)
Number of subjects: 4956
Study 17542047 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 4956
Study 16119514 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram from Eurofarma Laboratórios Ltda. (test formulation)
Number of subjects: 0
Study 16119514 — intervention group
Group type: COMPARATOR
Intervention: Cipramil from Schering‐Plough (reference formulation)
Number of subjects: 0
Study 12151431 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG
Number of subjects: 107
Study 12151431 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH
Number of subjects: 107
Study 12151431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (0.25 mg to 0.5 mg)
Number of subjects: 107
Study 12151431 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 107
Study 11225793 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy plus dual chamber pacemaker programmed to optimal AV delay (Group 2)
Number of subjects: 38
Study 11225793 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (Group 1)
Number of subjects: 38
Study 7562171 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple gloving with kevlar glove liners
Number of subjects: 30
Study 7562171 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple gloving with stainless steel glove liners
Number of subjects: 30
Study 7562171 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple layer latex gloving
Number of subjects: 30
Study 7562171 — intervention group
Group type: COMPARATOR
Intervention: Double latex gloving
Number of subjects: 30
Study 2187002 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) + Diazepam (DIA)
Number of subjects: 48
Study 2187002 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (CPZ) + Diazepam (DIA)
Number of subjects: 48
Study 7203001 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention program with nine months of weekly home visits
Number of subjects: 47
Study 31513046 — intervention group
Group type: EXPERIMENTAL
Intervention: DET
Number of subjects: 46
Study 31513046 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 μL NaFl
Number of subjects: 46
Study 31513046 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard strip
Number of subjects: 46
Study 31513046 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 μL NaFl
Number of subjects: 46
Study 31513046 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 μL NaFl (verification study)
Number of subjects: 46
Study 30500981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise intervention (3 times a week for 16 weeks)
Number of subjects: 100
Study 30500981 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 28972083 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CpG-B with GM-CSF
Number of subjects: 52
Study 28972083 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CpG-B without GM-CSF
Number of subjects: 52
Study 28972083 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 52
Study 28972083 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CpG-B with or without GM-CSF
Number of subjects: 52
Study 28972083 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CpG-B
Number of subjects: 52
Study 26541915 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 8399
Study 26541915 — intervention group
Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 8399
Study 23386328 — intervention group
Group type: EXPERIMENTAL
Intervention: Velaglucerase alfa 60 U/kg
Number of subjects: 25
Study 23386328 — intervention group
Group type: EXPERIMENTAL
Intervention: Velaglucerase alfa 45 U/kg
Number of subjects: 25
Study 21498386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactin‐V (Lactobacillus crispatus)
Number of subjects: 100
Study 21498386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21498386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactin‐V
Number of subjects: 100
Study 19539115 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-velocity, variable-amplitude spinal manipulation (LVVA-SM)
Number of subjects: 240
Study 19539115 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude spinal manipulation (HVLA-SM)
Number of subjects: 240
Study 19539115 — intervention group
Group type: COMPARATOR
Intervention: Minimal conservative medical care (MCMC)
Number of subjects: 240
Study 17043959 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound branch chain amino acid injection
Number of subjects: 50
Study 17043959 — intervention group
Group type: COMPARATOR
Intervention: Compound amino acid (control)
Number of subjects: 50
Study 14728606 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0
Study 14728606 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 0
Study 14728606 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Sulfadoxine-pyrimethamine and Chloroquine (SP+CQ)
Number of subjects: 0
Study 11766084 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate enteral nutrition (IEN)
Number of subjects: 24
Study 11766084 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (PAN)
Number of subjects: 24
Study 9266287 — intervention group
Group type: EXPERIMENTAL
Intervention: Angipress (50 mg)
Number of subjects: 18
Study 8503523 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-1 ganglioside
Number of subjects: 2
Study 8503523 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 2
Study 8503523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 3822681 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (3 mg/kg/d)
Number of subjects: 28
Study 3822681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3822681 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 28
Study 29934286 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention with telemonitoring guidance (weekly emails or phone calls)
Number of subjects: 90
Study 29934286 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based CR
Number of subjects: 90
Study 29934286 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care with advice to remain physically active)
Number of subjects: 90
Study 29934286 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based group
Number of subjects: 90
Study 27373088 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide treatment (1 ml budesonide suspension in gelatin sponges)
Number of subjects: 53
Study 27373088 — intervention group
Group type: COMPARATOR
Intervention: Control group (gelatin sponges only)
Number of subjects: 53
Study 27373088 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide treatment
Number of subjects: 53
Study 27373088 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 25093696 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway wall thickness
Number of subjects: 1138
Study 25093696 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema
Number of subjects: 1138
Study 25093696 — intervention group
Group type: EXPERIMENTAL
Intervention: Air trapping
Number of subjects: 1138
Study 22835916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 0
Study 22835916 — intervention group
Group type: COMPARATOR
Intervention: Observation after axillary ultrasound
Number of subjects: 0
Study 19879813 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-dose-rate (PDR) brachytherapy (PDRBT)
Number of subjects: 51
Study 19879813 — intervention group
Group type: COMPARATOR
Intervention: High-dose-rate (HDR) brachytherapy (HDRBT)
Number of subjects: 51
Study 18443762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified multi-factorial treatment
Number of subjects: 3057
Study 18443762 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (baseline characteristics)
Number of subjects: 3057
Study 16707993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 128
Study 16707993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 14667946 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking forwards on a hard surface, eyes open
Number of subjects: 11
Study 14667946 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking backwards on a foam support, eyes closed
Number of subjects: 11
Study 14667946 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking backwards on a soft surface (foam)
Number of subjects: 11
Study 14667946 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking backwards
Number of subjects: 11
Study 14667946 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking under increased locomotion difficulty
Number of subjects: 11